ADVANCE Post Hoc Analysis: CYP2B6 Genotype Associated With Differential Weight Gain in ART-Naive Patients Initiating Efavirenz-Based ART in South Africa

March 8-11, 2020; Boston, Massachusetts
Post hoc analysis found that patients initiating EFV-based ART who were categorized by CYP2B6 genotyping as slow metabolizers had less weight gain compared with extensive metabolizers and those initiating DTG-based ART.
Format: Microsoft PowerPoint (.ppt)
File Size: 176 KB
Released: March 14, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Related Content

Expert selections of important HIV data from IDWeek 2021, including current and investigational ART, HIV PrEP, and metabolic outcomes of ART.

Eric S. Daar, MD Darcy Wooten, MD Released: October 19, 2021

Limited treatment-emergent capsid resistance occurred after 28 weeks of treatment with oral or subcutaneous lenacapavir plus FTC/TAF from ID Week 2021 reported by Clinical Care Options (CCO)

Released: October 5, 2021

Diapositivas descargables creadas por expertos que analizan los desarrollos clínicos más importantes en el manejo del VIH desde el año pasado

Babafemi Taiwo, MBBS
Program Director
Rajesh T. Gandhi, MD Daniel R. Kuritzkes, MD Darcy Wooten, MD
Released: October 4, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue